Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALA-CORT vs ACETIC ACID W/ HYDROCORTISONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Acetic acid exerts antibacterial and antifungal activity by lowering p H and disrupting microbial cell membranes. Hydrocortisone is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (FDA),Off-label: Atopic dermatitis, psoriasis, contact dermatitis, lichen planus, discoid lupus erythematosus
Treatment of superficial bacterial infections of the external auditory canal (otitis externa) and associated inflammation.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
1 applicatorful (approximately 5 g) of the cream or ointment (containing 2% acetic acid and 1% hydrocortisone) inserted intravaginally once or twice daily for 7 days.
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Acetic acid: not applicable; hydrocortisone: plasma half-life ~1.5 hours (biologic half-life 8–12 hours). Due to low systemic absorption from topical application, systemic half-life is clinically irrelevant.
Topically applied; systemic absorption is minimal but can be increased with use on large areas, occlusive dressings, or damaged skin. Absorbed portion is metabolized primarily in the liver via hepatic microsomal enzymes (CYP3A4) and excreted by the kidneys.
Acetic acid is metabolized via the Krebs cycle to carbon dioxide and water. Hydrocortisone is primarily metabolized in the liver.
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Acetic acid: minimal systemic absorption; hydrocortisone: hepatic metabolism, renal excretion of metabolites (<5% unchanged). Less than 10% of applied dose excreted in urine as metabolites; biliary/fecal excretion negligible.
Hydrocortisone is approximately 90–95% bound to corticosteroid-binding globulin (CBG, transcortin) and albumin.
Hydrocortisone: ~90% bound to corticosteroid-binding globulin (CBG) and albumin. Acetic acid: negligible binding.
Apparent volume of distribution (Vd) is approximately 0.4–0.6 L/kg, indicating moderate tissue distribution and limited penetration into CNS.
Hydrocortisone: Vd ~0.3–0.5 L/kg (systemic); topical application results in negligible systemic distribution.
Topical: Bioavailability is negligible (<1%) through intact skin; may increase (up to 30%) with damaged skin or occlusive dressings. Rectal: Bioavailability is approximately 10–20% via mucosal absorption, with first-pass metabolism reducing systemic exposure.
Topical: ~1–5% of hydrocortisone absorbed through intact skin; higher with inflamed skin or occlusion. Acetic acid: negligible systemic absorption.
No adjustment required for topical use; systemic absorption minimal.
No dose adjustment required for acetic acid. Hydrocortisone is minimally affected by renal impairment; no specific adjustment recommended.
No adjustment required for topical use; hepatic metabolism negligible.
No dose adjustment required for acetic acid. For hydrocortisone, use with caution in severe hepatic impairment (Child-Pugh C) due to reduced metabolism; consider reducing frequency or dose, though no specific guidelines exist.
Children ≥2 years: Apply a thin film to affected area 2-3 times daily. Use lowest potency preparation; avoid prolonged use.
Safety and efficacy not established in pediatric patients; use not recommended.
Use lowest effective dose; monitor for skin atrophy and systemic effects due to thinner skin and increased percutaneous absorption.
No specific dose adjustment required. Use caution due to potential skin atrophy and systemic absorption; limit duration to minimum effective course.
None
Not applicable.
Systemic absorption may cause reversible HPA axis suppression,Cushing's syndrome, hyperglycemia, and glucosuria with prolonged use,Local adverse reactions: atrophy, striae, telangiectasias, acneiform eruptions, perioral dermatitis,May mask signs of infection,Use with caution in pediatric patients due to increased susceptibility to HPA axis suppression,Avoid use on face, intertriginous areas, and under occlusive dressings unless directed by physician
For otic use only; not for ophthalmic or systemic use.,Prolonged use may lead to fungal or bacterial superinfection.,Discontinue if irritation or sensitization develops.
Hypersensitivity to any component of the formulation,Untreated bacterial, viral, fungal, or parasitic skin infections,Viral skin infections (e.g., herpes simplex, varicella) at treatment site,Perioral dermatitis,Rosacea
Hypersensitivity to any component.,Viral or fungal infections of the external ear (e.g., herpes simplex, varicella).,Perforated tympanic membrane (risk of ototoxicity).
No known food interactions with topical ALA-CORT.
No clinically relevant food interactions. No specific dietary restrictions.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restriction, adrenal suppression in fetus. Avoid prolonged use.
Topical corticosteroids are generally considered low risk in pregnancy. Hydrocortisone is a weak corticosteroid. No increased risk of congenital malformations has been observed with topical use. Systemic absorption is minimal with small-area application. Avoid prolonged use on large areas, occlusive dressings, or high-potency steroids. Acetic acid has no known teratogenic risk.
Provides small amounts in breast milk; M/P ratio unknown. At maternal doses up to 80 mg/day, no adverse effects reported in infants. Consider risk-benefit with high doses or prolonged therapy.
Minimal systemic absorption of topical hydrocortisone and acetic acid; unlikely to affect the breastfed infant. Use on limited areas, avoid application to breast or nipple area. M/P ratio not established.
Pregnancy-induced pharmacokinetic changes (increased clearance, volume of distribution) may require increased dosing, but clinical response should guide adjustment. Avoid high doses and prolonged use.
No dosing adjustments required for pregnancy. Use lowest effective dose for shortest duration to minimize systemic absorption.
ALA-CORT (hydrocortisone acetate 2.5% and pramoxine HCl 1%) is a topical corticosteroid with anesthetic. Use for short-term relief of pruritus and inflammation in corticosteroid-responsive dermatoses. Avoid prolonged use on intertriginous or occluded areas. Limit to <2 weeks continuous use in adults to avoid skin atrophy. Not recommended for children <2 years.
Combination otic suspension for external otitis. Ensure tympanic membrane is intact before use; perforation risks ototoxicity. Shake well before instillation. Use for no longer than 10 days to avoid fungal overgrowth or adrenal suppression. Warm bottle in hands to avoid caloric vertigo. Contraindicated in viral or fungal infections of the ear canal.
Apply a thin layer to affected area no more than 3-4 times daily.,Do not cover with bandages or plastic unless directed by doctor.,Avoid contact with eyes, mouth, or broken skin.,Discontinue and notify doctor if infection, irritation, or no improvement after 7 days.,Do not use for diaper dermatitis or under diapers/occlusive dressings.,Keep out of reach of children.
For ear use only. Do not swallow or put in eyes.,Lie on side with affected ear upward for 5 minutes after instillation.,Keep ear clean and dry while using the medication.,Complete full course even if symptoms improve.,Do not use if you have a perforated eardrum; seek medical evaluation first.,Shake the bottle well before each use.
No interactions on record
"Hydrocortisone, a corticosteroid, may inhibit the hepatic metabolism of doxycycline, a tetracycline antibiotic, leading to increased doxycycline plasma concentrations. This elevation can potentiate doxycycline's adverse effects, such as gastrointestinal disturbance, photosensitivity, and hepatotoxicity. Clinically, this interaction may reduce the therapeutic window of doxycycline, requiring dose adjustment or alternative therapy selection."
"Fluconazole, a potent inhibitor of cytochrome P450 3A4 (CYP3A4), can significantly reduce the hepatic clearance of hydrocortisone, a corticosteroid metabolized primarily by CYP3A4. This interaction leads to increased systemic exposure to hydrocortisone, potentially resulting in exaggerated corticosteroid effects such as hyperglycemia, immunosuppression, and adrenal suppression. Clinically, patients may experience symptoms of Cushing's syndrome or require dose adjustments to avoid toxicity."
"Rifaximin, a non-systemic antibiotic primarily acting in the gastrointestinal tract, may inhibit intestinal P-glycoprotein (P-gp), reducing the efflux of corticosteroids like hydrocortisone. This can lead to increased systemic absorption and elevated serum concentrations of hydrocortisone, potentially enhancing both therapeutic and adverse effects such as hyperglycemia, immunosuppression, and adrenal suppression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALA-CORT vs ACETIC ACID W/ HYDROCORTISONE, answered by our medical review team.
ALA-CORT is a Topical Corticosteroid that works by Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.. ACETIC ACID W/ HYDROCORTISONE is a Corticosteroid that works by Acetic acid exerts antibacterial and antifungal activity by lowering p H and disrupting microbial cell membranes. Hydrocortisone is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALA-CORT and ACETIC ACID W/ HYDROCORTISONE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALA-CORT is: Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.. The standard adult dose of ACETIC ACID W/ HYDROCORTISONE is: 1 applicatorful (approximately 5 g) of the cream or ointment (containing 2% acetic acid and 1% hydrocortisone) inserted intravaginally once or twice daily for 7 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALA-CORT and ACETIC ACID W/ HYDROCORTISONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALA-CORT is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restri. ACETIC ACID W/ HYDROCORTISONE is classified as Category D/X. Topical corticosteroids are generally considered low risk in pregnancy. Hydrocortisone is a weak corticosteroid. No increased risk of congenital malformations has been observed wit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.